Halozyme Therapeutics Inc. (HALO) — RQD Stock Rating Cockpit
Halozyme Therapeutics Inc. (HALO) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
Real cash coming in backs up reported profits (84% profit margin and healthy balance-sheet cushion).
Big funds and company insiders are mostly holding steady without aggressive buying or panic selling.
No major SEC filing blowups, though current interest rates and Fed liquidity call for normal position sizing.
2-of-3 JEV AI Jury Bullish on HALO
18.0% ROIC with 83.6% gross margin and 4.33% FCF yield.
Altman-Z 5.11 and Piotroski 7/9 pass balance-sheet audit.
Put/Call 0.67x with 22/40 institutional & insider flow.
- ✓Strong cash generator (84% profit margin)—profits are backed by real money, not accounting tricks.
- ✓Clean SEC annual filing review with no major hidden accounting time-bombs.
- !Priced at 47x earnings—high expectations leave less room for a lukewarm quarter.
Today's Top 3 RQD Strong Buys & Whale Accumulation Setups (Live HALO Tape Review)
- ✓Live breakdown of today’s highest-scoring RQD Green-Light breakouts
- ✓1 urgent Red-Light accounting trap to cut from your watchlist immediately
- ✓Bring any ticker to live Q&A—we run it through the 5-Pillar RQD Radar on screen
HALO Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +37.6% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HALO today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HALO. Explore sector supply chains on /butterfly.
HALO Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDShould I buy, hold, or sell HALO stock right now?
Halozyme Therapeutics Inc. (HALO) currently earns a Roarable Rating of C+ (Hold — HOLD) with 67/100 RQD Confidence. Solid 84% profit margin (18% return on capital), mixed timing at 47x P/E—hold if owned, no rush to chase.
What is HALO's 12-month price target and RQD AI Jury consensus?
HALO's 12-month base price target is $136.49 (range $106.46 to $161.06), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.